MX345715B - Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa. - Google Patents

Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa.

Info

Publication number
MX345715B
MX345715B MX2012000298A MX2012000298A MX345715B MX 345715 B MX345715 B MX 345715B MX 2012000298 A MX2012000298 A MX 2012000298A MX 2012000298 A MX2012000298 A MX 2012000298A MX 345715 B MX345715 B MX 345715B
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
binding domain
extracellular
allosteric inhibitor
kinase receptor
Prior art date
Application number
MX2012000298A
Other languages
English (en)
Other versions
MX2012000298A (es
Inventor
Herbert Corentin
Carmeliet Peter
Desmet Frederik
Schymkowitz Joost
Rousseau Frédéric
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2012000298A publication Critical patent/MX2012000298A/es
Publication of MX345715B publication Critical patent/MX345715B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un dominio de unión extracelular para un inhibidor alostérico, de tal manera que dicho dominio de unión se derive de un receptor de tirosina quinasa de transmembrana único. Más específicamente, la invención se refiere a un dominio extracelular derivado de un receptor de factor de crecimiento de fibroblastos (FGFR). Se refiere además a la utilización de este dominio para la identificación de dominios similares en la parte extracelular de otros receptores tirosina quinasa, y a un método de selección para la identificación de un compuesto pequeño inhibidor alostérico.
MX2012000298A 2009-07-03 2010-07-02 Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa. MX345715B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290537A EP2270043A1 (en) 2009-07-03 2009-07-03 Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
PCT/IB2010/053054 WO2011001413A1 (en) 2009-07-03 2010-07-02 Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor

Publications (2)

Publication Number Publication Date
MX2012000298A MX2012000298A (es) 2013-05-30
MX345715B true MX345715B (es) 2017-02-13

Family

ID=41137351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000298A MX345715B (es) 2009-07-03 2010-07-02 Dominio de union extracelular de inhibidor alosterico de un receptor tirosina quinasa.

Country Status (17)

Country Link
US (2) US9234025B2 (es)
EP (2) EP2270043A1 (es)
JP (2) JP6255156B2 (es)
KR (1) KR101828092B1 (es)
CN (1) CN102596991B (es)
AU (1) AU2010267590B2 (es)
BR (1) BR112012000029B8 (es)
CA (1) CA2766972C (es)
DK (1) DK2448964T3 (es)
ES (1) ES2631452T3 (es)
HU (1) HUE035052T2 (es)
IL (1) IL217155B (es)
MX (1) MX345715B (es)
MY (1) MY158993A (es)
RU (1) RU2604805C2 (es)
SG (2) SG10201403778TA (es)
WO (1) WO2011001413A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
CA2940322C (en) 2014-02-21 2021-05-18 President And Fellows Of Harvard College De novo design of allosteric proteins
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
WO2018081534A1 (en) 2016-10-28 2018-05-03 President And Fellows Of Harvard College Assay for exo-site binding molecules
WO2018237041A1 (en) * 2017-06-22 2018-12-27 The Regents Of The University Of Michigan SPECIFIC PEPTIDE REAGENTS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS
EP3710483A4 (en) * 2017-11-16 2021-10-20 XL-protein GmbH PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY
CN111712245A (zh) 2018-03-28 2020-09-25 卫材R&D管理有限公司 用于肝细胞癌的治疗剂
CN113651662B (zh) * 2020-12-31 2023-10-27 复旦大学附属华山医院 一种靶向fgfr的新型肿瘤pet分子探针及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0302548A2 (hu) * 2000-05-11 2003-11-28 Wyeth G-fehérje-jeltovábbítás szabad regulátorának szerkezete, valamint eljárások agonisták és antagonisták azonosítására a szerkezet alkalmazásával
US7393656B2 (en) * 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
US7083933B1 (en) * 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
DK1758986T3 (en) * 2004-06-09 2016-01-18 Univ Edinburgh Neural stem cells
WO2006113485A2 (en) * 2005-04-15 2006-10-26 Board Of Trustees Of Michigan State University Aminergic pharmaceutical compositions and methods
FR2896247B1 (fr) 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases

Also Published As

Publication number Publication date
US9234025B2 (en) 2016-01-12
KR101828092B1 (ko) 2018-02-09
CA2766972A1 (en) 2011-01-06
DK2448964T3 (en) 2017-07-24
MX2012000298A (es) 2013-05-30
JP6255156B2 (ja) 2017-12-27
EP2448964A1 (en) 2012-05-09
IL217155B (en) 2019-01-31
ES2631452T3 (es) 2017-08-31
AU2010267590B2 (en) 2016-08-04
KR20120093146A (ko) 2012-08-22
BR112012000029B1 (pt) 2020-12-08
HUE035052T2 (en) 2018-05-02
CN102596991B (zh) 2016-06-08
SG10201403778TA (en) 2014-10-30
JP2012532121A (ja) 2012-12-13
CA2766972C (en) 2019-03-05
EP2448964B1 (en) 2017-04-12
AU2010267590A1 (en) 2012-02-02
RU2604805C2 (ru) 2016-12-10
US20160193192A1 (en) 2016-07-07
WO2011001413A1 (en) 2011-01-06
SG177427A1 (en) 2012-02-28
CN102596991A (zh) 2012-07-18
IL217155A0 (en) 2012-02-29
BR112012000029A2 (pt) 2016-11-08
BR112012000029B8 (pt) 2021-05-25
US20120094864A1 (en) 2012-04-19
EP2270043A1 (en) 2011-01-05
RU2012103542A (ru) 2013-08-10
MY158993A (en) 2016-11-30
JP2017036305A (ja) 2017-02-16

Similar Documents

Publication Publication Date Title
MY158993A (en) Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
EP2376495A4 (en) COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS
HK1124619A1 (en) Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk alk
MY155621A (en) Axl antibodies
IL239156A0 (en) Broton tyrosine kinase inhibitors
HK1216887A1 (zh) 布魯頓酪氨酸激酶的抑制劑
MX2011011825A (es) Anticuerpos humanizados para axl.
IL208882A0 (en) Inhibitors of protein tyrosine kinase activity
ZA201001512B (en) Inhibitors of protein tyrosine kinase activity
TN2011000673A1 (en) Bace inhibitors
IL218543A0 (en) Pyrimidine derivatives as protein tyrosine kinase 2 inhibitors
ZA201202552B (en) Inhibitors of bruton's tyrosine kinase
CR11776A (es) Inhibidores de bace
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
EA201070856A1 (ru) Кристаллические формы диметоксидоцетаксела и способы их получения
EP2484678A4 (en) SUBSTITUTED 4- (ANILINO) DERIVATIVES QUINAZOLINE AS TYROSINE KINASE INHIBITORS
EA201270350A1 (ru) Способ идентификации и получения (r)-специфической омега-трансаминазы
ZA200900019B (en) Tyrosine kinase inhibitors
CL2011000295A1 (es) Compuestos derivados de pirimidil-amino-benzamida; inhibidores de tirosin-quinasa; y su uso en el tratamiento de la hipertension pulmonar.
MX2009012474A (es) Compuestos de quinazolina.
EP2247185A4 (en) INHIBITORS OF TYROSINE KINASE
ATE557019T1 (de) Pyrrolidin-3-ylmethyl-amin als orexin- antagonisten
MX2010012408A (es) Metodos para predecir la respuesta de un paciente a los inhibidores del egfr.
DE602005019090D1 (de) Pyrrolidin-2-on-Derivate zur Verwendung als DP1-Rezeptoragonisten
TH104263B (th) สารยับยั้งของแอคติวิตี้ของโปรตีนไทโรซีนไคเนส

Legal Events

Date Code Title Description
FG Grant or registration